Want to create an interactive transcript for this episode?
Podcast: PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Episode: Stephen V. Liu, MD - A Bold Frontier: Shattering the Limits of Conventional Therapies and Reshaping the Future of Lung Cancer Treatment With TROP2-Targeting ADCs and Rational Combinations
Description: Go online to PeerView.com/WFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent unique, potent, and promising new options in the lung cancer treatment arsenal. Ongoing clinical trials evaluating ADCs, including those directed at trophoblast cell surface antigen 2 (TROP2), have demonstrated positive preliminary data in lung cancer, and additional results from other studies assessing monotherapy and rational combinatorial options are anticipated in the near future. As advances with TROP2-targeting ADCs continue, it is crucial for oncologists and other professionals involved in the care of patients wi...